The Cerebrospinal Fluid Free-Glycans Hex1 and HexNAc1Hex1Neu5Ac1 as Potential Biomarkers of Alzheimer’s Disease
Open Access
- 24 April 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (5) , 512
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting a growing number of elderly people. In order to improve the early and differential diagnosis of AD, better biomarkers are needed. Glycosylation is a protein post-translational modification that is modulated in the course of many diseases, including neurodegeneration. Aiming to improve AD diagnosis and differential diagnosis through glycan analytics methods, we report the glycoprotein glycome of cerebrospinal fluid (CSF) isolated from a total study cohort of 262 subjects. The study cohort consisted of patients with AD, healthy controls and patients suffering from other types of dementia. CSF free-glycans were also isolated and analyzed in this study, and the results reported for the first time the presence of 19 free glycans in this body fluid. The free-glycans consisted of complete or truncated N-/O-glycans as well as free monosaccharides. The free-glycans Hex1 and HexNAc1Hex1Neu5Ac1 were able to discriminate AD from controls and from patients suffering from other types of dementia. Regarding CSF N-glycosylation, high proportions of high-mannose, biantennary bisecting core-fucosylated N-glycans were found, whereby only about 20% of the N-glycans were sialylated. O-Glycans and free-glycan fragments were less sialylated in AD patients than in controls. To conclude, this comprehensive study revealed for the first time the biomarker potential of free glycans for the differential diagnosis of AD.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BL-1436/2-1, PE-1878/3-1)
- Sonnenfeld Foundation (BL-1436/2-1, PE-1878/3-1)
- Open Access Publication Fund of Charité—Universitätsmedizin Berlin and the German Research Foundation (BL-1436/2-1, PE-1878/3-1)
This publication has 95 references indexed in Scilit:
- 2021 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2021
- CSF N‐glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorderAutism Research, 2015
- Evaluation of a combined glycomics and glycoproteomics approach for studying the major glycoproteins present in biofluids: Application to cerebrospinal fluidRapid Communications in Mass Spectrometry, 2015
- Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensityInternational Journal of Geriatric Psychiatry, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- The neuropathology of probable Alzheimer disease and mild cognitive impairmentAnnals of Neurology, 2009
- “Glyco‐peakfinder” – de novo composition analysis of glycoconjugatesProteomics, 2007
- Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathyMovement Disorders, 2001
- Clinical and Pathological Evidence for a Frontal Variant of Alzheimer DiseaseArchives of Neurology, 1999
- A kinematic study of progressive apraxia with and without dementiaMovement Disorders, 1999